anti-survivin T-cell receptor/anti-CD3 bispecific therapeutic ABBV-184

A T-cell redirecting bispecific therapeutic composed of a T-cell receptor (TCR) moiety specific for the tumor-associated antigen (TAA) survivin and a CD3 binding moiety, with potential immunostimulating and antineoplastic activities. Upon administration of anti-survivin TCR/anti-CD3 bispecific therapeutic ABBV-184, the TCR moiety of this agent targets and binds to survivin on tumor cells and the anti-CD3 moiety binds to CD3-expressing T lymphocytes. This selectively cross-links tumor cells and T lymphocytes and results in a CTL-mediated killing of survivin-expressing tumor cells. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.